Deciphera Pharmaceuticals Inc. [NASDAQ: DCPH] plunged by -$0.46 during the normal trading session on Tuesday and reaching a high of $11.45 during the day while it closed the day at $10.65. The company report on January 3, 2022 that Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 9:00 AM ET.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.
Deciphera Pharmaceuticals Inc. stock has also gained 5.86% of its value over the past 7 days. However, DCPH stock has declined by -67.44% in the 3 months of the year. Over the past six months meanwhile, it has lost -69.15% and gained 9.01% year-on date.
The market cap for DCPH stock reached $641.98 million, with 58.11 million shares outstanding and 41.47 million shares in the current float. Compared to the average trading volume of 2.26M shares, DCPH reached a trading volume of 3928951 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Deciphera Pharmaceuticals Inc. [DCPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DCPH shares is $12.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DCPH stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Deciphera Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 08, 2021. While these analysts kept the previous recommendation, Canaccord Genuity dropped their target price from $72 to $12. The new note on the price target was released on November 08, 2021, representing the official price target for Deciphera Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $50 to $11, while Barclays kept a Equal Weight rating on DCPH stock. On November 05, 2021, analysts decreased their price target for DCPH shares from 65 to 10.
The Average True Range (ATR) for Deciphera Pharmaceuticals Inc. is set at 0.73, with the Price to Sales ratio for DCPH stock in the period of the last 12 months amounting to 7.02. The Price to Book ratio for the last quarter was 1.63, with the Price to Cash per share for the same quarter was set at 5.68.
DCPH stock trade performance evaluation
Deciphera Pharmaceuticals Inc. [DCPH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.86. With this latest performance, DCPH shares gained by 33.12% in over the last four-week period, additionally sinking by -69.15% over the last 6 months – not to mention a drop of -80.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DCPH stock in for the last two-week period is set at 48.98, with the RSI for the last a single of trading hit 57.55, and the three-weeks RSI is set at 42.13 for Deciphera Pharmaceuticals Inc. [DCPH]. The present Moving Average for the last 50 days of trading for this stock 13.75, while it was recorded at 10.19 for the last single week of trading, and 30.04 for the last 200 days.
Deciphera Pharmaceuticals Inc. [DCPH]: An insightful look at the core fundamentals
Deciphera Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.00 and a Current Ratio set at 5.10.
Earnings per share (EPS) analysis for Deciphera Pharmaceuticals Inc. [DCPH] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DCPH. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Deciphera Pharmaceuticals Inc. go to 21.00%.
Deciphera Pharmaceuticals Inc. [DCPH]: Insider Ownership positions
There are presently around $475 million, or 75.40% of DCPH stock, in the hands of institutional investors. The top three institutional holders of DCPH stocks are: REDMILE GROUP, LLC with ownership of 4,031,521, which is approximately -5.023% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 3,936,385 shares of the stock with an approximate value of $43.73 million in DCPH stocks shares; and BLACKROCK INC., currently with $41.05 million in DCPH stock with ownership of nearly 0.372% of the company’s market capitalization.
79 institutional holders increased their position in Deciphera Pharmaceuticals Inc. [NASDAQ:DCPH] by around 4,298,302 shares. Additionally, 62 investors decreased positions by around 4,300,419 shares, while 28 investors held positions by with 34,137,594 shares. The mentioned changes placed institutional holdings at 42,736,315 shares, according to the latest SEC report filing. DCPH stock had 27 new institutional investments in for a total of 1,948,529 shares, while 12 institutional investors sold positions of 983,173 shares during the same period.